Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 3:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Gel Clear all
Terminated Phase 2 Interventional Results available

Development of A Novel Anti-Hyperglycemic Agent

NCT00878605
View directory record Official record
Conditions
Diabetes
Interventions
Cyclo-Z, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 4, 2026, 3:34 PM EDT
Not yet recruiting Not applicable Interventional

Gastric Ultrasound in Patients Who Have Undergone Bariatric Surgery

NCT07310875
View directory record Official record
Conditions
Obesity, Weight Loss, Gastrectomy
Interventions
Gastric Point of Care Ultrasound
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

NCT01584531
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS, Trisomy 8
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants

NCT04088357
View directory record Official record
Conditions
Wound Healing
Interventions
TolaSure Topical Gel, Topical Vehicle Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 4, 2026, 3:34 PM EDT
Withdrawn Phase 2 Interventional

Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

NCT01408056
View directory record Official record
Conditions
Infantile Hemangiomas
Interventions
Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 8 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00357994
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 4, 2026, 3:34 PM EDT
Terminated Not applicable Interventional

Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation

NCT01315951
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Petroleum Jelly
Biological
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Burton, Michigan
Source: ClinicalTrials.gov public record
Updated May 19, 2024 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Phase 3 Interventional

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

NCT02393937
View directory record Official record
Conditions
Papulopustular Rosacea, Erythematotelangiectatic Rosacea
Interventions
Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%, Placebo Gel
Drug
Lead sponsor
bioRASI, LLC
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
27
States / cities
Los Angeles, California • San Diego, California • Boca Raton, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 4, 2026, 3:34 PM EDT
Not listed Phase 2 Interventional

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea

NCT03667222
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
minocycline topical gel, topical gel vehicle
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Anaheim Hills, California • Miami, Florida • Miramar, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Phase 2 Interventional

COL-1077 (Lidocaine Bioadhesive Gel, 10%) in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy

NCT02465320
View directory record Official record
Conditions
Endometrial Biopsy
Interventions
COL-1077, Placebo
Drug
Lead sponsor
Juniper Pharmaceuticals, Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
23
States / cities
Norwalk, California • Colorado Springs, Colorado • Lakewood, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Phase 2 Interventional

Topical SGX302 for Mild-to-Moderate Psoriasis

NCT05442190
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris
Interventions
Hypericin
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Not applicable Interventional

Vitamin D to Improve Glucose Metabolism and Reduce Inflammation in Obese Adolescents

NCT00994396
View directory record Official record
Conditions
Obesity, Glucose Intolerance, Inflammation
Interventions
Placebo, Vitamin D 3 cholecalciferol
Dietary Supplement
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
9 Years to 19 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Phase 3 Interventional

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

NCT02865005
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan)
Drug · Other
Lead sponsor
Seegpharm S.A.
Industry
Eligibility
12 Years to 40 Years
Enrollment
2,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
35
States / cities
Encino, California • Fullerton, California • La Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 4, 2026, 3:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Analysis of Diphenylcyclopropenone (DPCP) in Normals

NCT01452594
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Diphenylcyclopropenone, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 4, 2026, 3:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Non-invasive Stimulation of the Glymphatic System for Slowing Cognitive Decline

NCT07044596
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Post Concussion Syndrome
Interventions
Functional near-infrared spectroscopy (fNIRS), V1 stimulation electrodes, Magnetic Resonance Imaging (MRI), MAGNUS scanner
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
20 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color

NCT01012388
View directory record Official record
Conditions
Nasolabial Folds
Interventions
Radiesse® Injectable Dermal Filler
Device
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
Los Angeles, California • Chevy Chase, Maryland • Ypsilanti, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Not applicable Interventional

Prospective Nail Polish Study

NCT05181761
View directory record Official record
Conditions
Bacterial Growth
Interventions
Gel Polish
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability of SPL7013 Gel (VivaGel™) in Sexually Active Women

NCT00442910
View directory record Official record
Conditions
Healthy
Interventions
3% SPL7013 Gel (VivaGel), Placebo Gel, HEC Placebo Gel
Drug
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
18 Years to 24 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Tampa, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2010 · Synced Sep 4, 2026, 3:34 PM EDT
Not listed Phase 4 Interventional

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

NCT03066869
View directory record Official record
Conditions
Uveitis, Posterior, Vasculitis Retinal
Interventions
H.P. ACTHAR GEL
Drug
Lead sponsor
Ocular Immunology and Uveitis Foundation
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 4, 2026, 3:34 PM EDT
Recruiting Not applicable Interventional

Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause

NCT05672901
View directory record Official record
Conditions
Genitourinary Syndrome of Menopause
Interventions
StrataMGT, Estrace 0.01% Vaginal Cream
Device · Drug
Lead sponsor
Stratpharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Laguna Hills, California • Miami, Florida • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Not applicable Interventional

Improved Intra-operative Safety From Optimal Selection of Anti-slip Surface

NCT03573557
View directory record Official record
Conditions
Vaginal Surgery, Laparoscopic Surgery
Interventions
Pink Pad, Bean Bag, Gel Pad
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

Effects of BufferGel and PRO 2000/5 Gel in Men

NCT00016536
View directory record Official record
Conditions
HIV Infections
Interventions
Naphthalene 2-sulfonate polymer, Carbopol polymer
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 4, 2026, 3:34 PM EDT
Withdrawn Phase 4 Interventional

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

NCT02028312
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Loteprednol etabonate, Artificial Tears, Restasis
Drug
Lead sponsor
Edward Holland, MD
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Edgewood, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 4, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

NCT05882812
View directory record Official record
Conditions
Osteo Arthritis Knee, Arthritis
Interventions
Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac Patches
Device · Drug
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Stamford, Connecticut • Trumbull, Connecticut • Dryden, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 4, 2026, 3:34 PM EDT